BUZZ-Dexcom rises after forecasting 2025 revenue in-line with estimates

Medical device maker Dexcom's DXCM.O shares rise 5.2% to $81.52 premarket

Co forecasts 2025 revenue of $4.60 bln, in-line with analysts' estimates of $4.61 bln as per data compiled by LSEG

Co in August launched its over-the-counter device Stelo in the U.S. for adults aged 18 and older who do not use insulin, making it the first continuous glucose monitor available for over-the-counter sales

Co says the forecast was driven in part by "increasing CGM access and awareness for people with diabetes, the continued rollout of Stelo"

Reports preliminary Q4 revenue of at least $1.11 bln vs analysts' estimates of $1.10 bln

Stock had fallen 37.3% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))